Am-Pharma B.V.

8 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Apr 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 5, 2027
The maintenance fee for Chimeric alkaline phosphatase-like proteins (US 11,746,340) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
1 fee due Aug 25, 2027
The maintenance fee for Downstream Processing of an Alkaline Phosphatase (US 10,570,380) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 8,557,545	Modified phosphatases In force Term ends Apr 23, 2029 · From the USPTO record	In force	Term ends Apr 23, 2029	From the USPTO record
US 8,586,032	Use of alkaline phosphatase in the treatment of reduced renal function In force Term ends Feb 10, 2030 · From the USPTO record	In force	Term ends Feb 10, 2030	From the USPTO record
US 9,926,544	Chimeric alkaline phosphatase-like proteins In force Term ends Jan 26, 2035 · From the USPTO record	In force	Term ends Jan 26, 2035	From the USPTO record
US 10,822,597	Chimeric alkaline phosphatase-like proteins In force Ends no later than Jan 26, 2035 · From the USPTO record	In force	Ends no later than Jan 26, 2035	From the USPTO record
US 11,746,340	Chimeric alkaline phosphatase-like proteins In force Ends no later than Jan 26, 2035 · From the USPTO record	In force	Ends no later than Jan 26, 2035	From the USPTO record
US 12,534,713	Chimeric Alkaline Phosphatase-Like Proteins In force Term ends Jan 26, 2035 · Low confidence	In force	Term ends Jan 26, 2035	Low confidence
US 10,570,380	Downstream Processing of an Alkaline Phosphatase In force Ends no later than Apr 24, 2035 · Medium confidence	In force	Ends no later than Apr 24, 2035	Medium confidence
US 12,178,857	Recombinant Alkaline Phosphatase for Use in Treating Sepsis-Associated Acute Kidney Injury In force Term ends Jan 17, 2041 · High confidence	In force	Term ends Jan 17, 2041	High confidence

Also on record, not counted in the 8: 3 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 2 abandoned · 6 no status recorded

List them